Sample Setting, Size	Data/ Source(s)	Prevalence: Overall & Symptoms	Functional Measure: Disability, Activity, Quality of Life (QOL)			
Centers for Disease Control and Prevention/ National Center for Health Statistics Long Covid; Household Pulse Survey (website) Link						
<ul> <li>National Center for Health Statistics (<u>NCHS</u>) (items) + US Census (sampling frame)</li> </ul>	<ul> <li>6/2022</li> <li>Online - text &amp; email recruit</li> <li>Panels</li> <li>Experimental</li> </ul>	Long Covid Definition: Covid >= 3 months prior;         Specific queries range of Long Covid symptoms, e.g., fatigue, brain fog. As of April 2023:         • Ever Had Long Covid:         • % All US adults:       15.1%         • % who ever had Covid:       27.8%         • Currently Have Long Covid:       5.6%         • % who ever had Covid:       10.1%	Activity Limitations from Long Covid. as of April 2023         • Among All US Adults: <ul> <li>Any activity limits</li> <li>Significant limits</li> <li>4.6 %</li> </ul> • Among Adults Who Currently Have Long Covid: <ul> <li>Any activity limits:</li> <li>79%%</li> <li>Significant limits:</li> <li>23.6%=</li> </ul>			
Long COVID at	nd Significant Activity Limitation Am	Ford et. al., 2023 <sup>1</sup> ong Adults, by Age — United States, June 1–13, 2	022, to June 7–19, 2023			
<ul> <li>National Center for Health Statistics (<u>NCHS</u>) (items) + US Census (sampling frame)</li> <li>Subset w Current</li> </ul>	<ul> <li>6/2022-6/2023</li> <li>Online - text &amp; email recruit</li> <li>Panels</li> <li>Experimental</li> </ul>	Long Covid Definition: Covid >= 3 months prior, June 2023 <ul> <li><u>Among Adults w Current LC:</u></li> <li>Limited "A lot " 26.4% (95% CI: 24.0-8.9)</li> </ul>	Persistence of Significant Activity Limitations from Long Covid, Prevalence- of significant activity lits- stable over 1 year study period (-0.05% change per cycle, p=0.72)			
Physical and M	Mental Health Disability Associated w	Lau et. al., 2023. <sup>2</sup> ith Long-Covid: Baseline Results From a US Natio	onwide Cohort. LINK			
<ul> <li>Hopkins Study (US)</li> <li>18+ years</li> <li>Hospital + Non-Hospital</li> <li>Baseline Status: <ul> <li>Long Covid: 7,926</li> <li>Resolved: 948</li> <li>Never: 633</li> </ul> </li> </ul>	<ul> <li>1/2020-6/2022</li> <li>Prospective</li> <li>Online survey</li> <li>Social media &amp; community</li> </ul>	Long Covid Definition: Covid >= 3 months prior	Long Covid Group: • 65% had >= 1 disability • <u>Mobility</u> (difficult: walk ¼ mile or 10 steps) = 41% • <u>IADL</u> - some difficulty= 57% • <u>Mental fatigue</u> , severe= 6.7%			
Long-Terr	n Consequences of Asymptomatic SA	Ma et. al, 2023: <sup>3</sup> RS-CoV-2 Infection: A Systematic Review and Me	eta-Analysis. <u>Link</u>			
<ul> <li>3 Countries- not US*</li> <li>941* (adults)</li> <li>Criteria: &gt;= 3 month follow up</li> <li>Asymptomatic- no symptoms at time of (+) test</li> <li>Symptomatic- not defined</li> <li>2020 &amp; 2021†</li> <li>Observational Cohort Studies</li> </ul>		Long Covid Definition: unstated, but criteria for study entry: >= 3-month follow-up <u>Prevalence</u> - Asymptomatic Adults: • >= 1 Symptom. 21% • Fatigue. 15% • Muscle/Joint. 9% • Dyspnea. 9% <u>Asymptomatic v Symptomatic:</u> • OR for >= 1 Symptom: 0.80	NA			
Long-	Ferm Consequences of Covid 19 at 6 M	Ma et. al., 2022: <sup>4</sup> Ionths and Above: A Systematic Review and Meta-A	Analysis. <u>Link</u>			
<ul> <li>Global</li> <li>10,945 cases/40 studies</li> <li>Criteria: &gt;=6-month Follow-up</li> </ul>	<ul><li>&lt; 2/9/2022</li><li>Observational cohort studies</li></ul>	Long Covid Definition: >=6-month post-PCR confirmed Covid*         Prevalence: 6-12 months/ > 12 months:         • Long Covid:       64% / 59%         • Fatigue/muscle weak:       54% / 34%	Impact on Quality of Life:@ 6-12 months/ @> 12 months:• Pain/discomfort33% / 35%• Usual activity7%/11%• Personal care1% /1%			

		2		
• NA: age, hospital, symptomatic		<ul> <li>Dyspnea: 75% / 81%</li> <li>Anxious/depressed: 33% / 35%</li> </ul>	• Mobility 10% / 9%	
	Prevalence and Correlates of	Perlis et. al. ,2022: <sup>5</sup> Long Covid Symptoms Among US Adults. <u>Link</u>		
<ul> <li>Covid States Project- 8 waves (US)</li> <li>16,091; had Covid</li> </ul>	<ul> <li>2/2021-7/2022</li> <li>Non-probability sample</li> <li>Internet sample</li> </ul>	Long Covid Definition: Covid >= 2 months prior <u>Prevalence</u> = 14.7% <u>US Est. Prevalence</u> = 13.9% <u>See Table:</u> fatigue (52%), brain fog or memory (46% s), shortness of breath (40%)	NA	
Sample Setting, Size	Data/ Source(s)	Prevalence: Overall & Symptoms	Functional Measure: Disability, Activity, Quality of Life (QOL)	
Sy		Rahmati et. al. 2023: <sup>6</sup> ong-term sequelae of COVID-19 2-year after infec	tion. <u>Link</u>	
<ul> <li>Global/12 studies</li> <li>Total n= 1, 289,044</li> <li>Criteria: <ul> <li>&gt;= 2 years post-covid</li> <li>&gt;=1 outcome: heart GI, skin, respiratory, neurologic, psych</li> </ul> </li> <li>Adults 18+</li> <li>Hospital rate: 2%-100%</li> </ul>	• Cohort studies	Long Covid Definition: NA; >= 2 years post <u>Prevalence:</u> 41.7%. (>=1 symptom) Symptom @ 2 years: 2-year v 1-year: Fatigue- 27%. Same* Sleep- 25%. Better Dyspnea- 10%. Same Anxiety- 9%. No data Focus- 8% No data Myalgia- 6%. Same	NA	
		obertson et. al. 2023: <sup>7</sup> ong Coronavirus Disease in US Adults <u>Link</u>		
•US •N=3,024 •English & Spanish	<ul> <li>June/July 2022</li> <li>Survey</li> <li>64% landline</li> <li>Census-weighted</li> <li>Age &amp; Gender- adjusted</li> </ul>	Long Covid Definition: Covid >= 4 weeks prior + fatigue, concentration and/or shortness of breath <u>Prevalence</u> = 7.3%* (n= 222) <u>US Estimate Prevalence</u> = 18.8 mil *Pulse 7/22 data= 7.5%*	<ul> <li>Limits on (ADLs) among n=222 with Long Covid (est. US prevalence):</li> <li>A lot: 25% (4.8 mil)</li> <li>A little: 50% (9.3 mil)</li> <li>None: 25% (4.7 mil)</li> <li>*Pulse ADL data, Sept-Dec 22: 79% any limit &amp; 25% significant limit among those with current Long Covid*</li> </ul>	
	Estimating Total Morbidity Burden C	Smith M., 2022: <sup>8</sup> of COVID-19: Relative Importance Of Death And	Disability	
<ul> <li>NA: Burden models based on estimates</li> <li>No data collected</li> </ul>	NA	<ul> <li>Long Covid Definition: NA, but cites Covid &amp; ME/CFS: fatigue, muscle/body ache &amp; difficulty concentrating.</li> </ul>	<ul> <li>Model 1 treats Long Covid like ME/CFS &amp; thus applies ME/CFS Disability weights per prior work:</li> <li>Mild CFS: 0.14</li> <li>Moderate CFS: 0.45</li> <li>Severe CFS: 0.76</li> </ul>	
		Woodrow et.al. 2023 <sup>9</sup> of the Prevalence of Long Covid. <u>Link</u>		
<ul> <li>China, Europe, NA, Others</li> <li>120 studies: Cohort, Cross-Sectional, Case- Control</li> <li>Community + Hospital + Both</li> </ul>	<ul><li>1/2020-11/2022</li><li>Systematic Review</li><li>Adults &amp; Children</li></ul>	<ul> <li>Long Covid Definition: IF &gt;= 3 months self-report of COVID or (+) test:</li> <li>Persistent symptoms, and/or</li> <li>Functional disability, and/or</li> <li>New pathology</li> <li>Prevalence: Overall: 42% (95% CI: 7%-88%)</li> <li>Fatigue: 22%</li> <li>Breathing problems: 15%</li> </ul>	<ul> <li><u>Function:</u></li> <li>Not Full Health/Fitness: 35% (8%-70%)</li> <li>Overall- wide ranges, somewhat higher among self-reported</li> </ul>	
	Wul	f-Hanson & Vos. 2022: <sup>10</sup>		

Estimated Global Proportions of Individuals with Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. Link				
<ul> <li>22 countries</li> <li>54 studies</li> <li>1.2 million medical records</li> <li>Symptomatic only</li> </ul>	<ul> <li>3/2020-1/2022</li> <li>Medical Records</li> <li>Hospitalized &amp; Non-Hospitalized</li> <li>&lt;20 years &amp; &gt;=20 years</li> </ul>	Long Covid Definition: Covid >= 3 months prior Global Prevalence: 6.2% • Fatigue cluster- 3.2% • Cognitive cluster- 2.2% • Respiratory cluster- 3.7% # of Symptom Clusters • 1 Symptom= 61.6% • 2 Symptoms= 24.4% • 3 Symptoms= 8.5% Females: app.2x as MALES	Disability Weight By Level: (mild/moderate/severe)         • Fatigue:       0.22 (1 level)         • Cognitive:       0.07/0.38 (mild/severe)         • Respiratory:       0.02/0.23/0.41         Authors note that on average, living with Long Covid is associated with losing 21% of health. <sup>11</sup>	

- Ford ND, Slaughter D, Edwards D, et al. Long COVID and Significant Activity Limitation Among Adults, by Age - United States, June 1-13, 2022, to June 7-19, 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(32):866-870.
- 2. Lau B, Wentz E, Ni Z, et al. Physical Health and Mental Fatigue Disability Associated with Long COVID: Baseline Results from a US Nationwide Cohort. *Am J Med.* 2023.
- 3. Ma Y, Deng J, Liu Q, Du M, Liu M, Liu J. Long-Term Consequences of Asymptomatic SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health.* 2023;20(2).
- 4. Ma Y, Deng J, Liu Q, Du M, Liu M, Liu J. Long-Term Consequences of COVID-19 at 6 Months and Above: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health*. 2022;19(11).
- 5. Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and Correlates of Long COVID Symptoms Among US Adults. *JAMA Netw Open.* 2022;5(10):e2238804.
- 6. Rahmati M, Udeh R, Yon DK, et al. A systematic review and meta-analysis of long-term sequelae of COVID-19 2-year after SARS-CoV-2 infection: A call to action for neurological, physical, and psychological sciences. *J Med Virol.* 2023;95(6):e28852.
- 7. Robertson MM, Qasmieh SA, Kulkarni SG, et al. The Epidemiology of Long Coronavirus Disease in US Adults. *Clin Infect Dis.* 2023;76(9):1636-1645.
- 8. Smith MP. Estimating total morbidity burden of COVID-19: relative importance of death and disability. *J Clin Epidemiol.* 2022;142:54-59.
- 9. Woodrow M, Carey C, Ziauddeen N, et al. Systematic Review of the Prevalence of Long COVID. *Open Forum Infect Dis.* 2023;10(7):ofad233.
- 10. Wulf Hanson S, Abbafati C, Aerts JG, et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604-1615.
- 11. National Academies of Engineering SaM. Long COVID Examining Long-Term Health Effects of COVID-19 and Implications for the Social Security Administration: Proceedings of a Workshop. 2022.

Comparison of Long Covid Symptoms: Global Burden of Disease vs. Household Pulse Survey

**Global Burden of Disease**- Health states, symptom descriptions and disability weight for the 3 Long Covid symptom clusters identified by the GBD Long Covid Study\*

Symptom cluster	Health state	Symptom description	Disability weight (95% UI)	
Ongoing respiratory problems				
	Mild chronic respiratory problems	Cough and shortness of breath after heavy physical activity, but able to walk long distances and climb stairs	0.02 (0.01-0.04)	
	Moderate chronic respiratory problems	Cough, wheezing, and shortness of breath even after light physical activity; feel tired and can only walk short distances or climb a few stairs	0.23 (0.15-0.31)	
	Severe chronic respiratory problems	Cough, wheezing, and shortness of breath all the time; great difficulty walking even short distances or climbing any stairs, feel tired when at rest, and have anxiety	0.41 (0.27-0.56)	
Cognitive problems				
Mild symptoms <sup>b</sup>	Mild cognitive problems	Some trouble remembering recent events and find it hard to concentrate and make decisions and plans	0.07 (0.05-0.10)	
	Moderate cognitive problems	Memory problems and confusion, feel disoriented, hear voices sometimes that are not real, and need help with some daily activities	0.38 (0.25-0.51)	
	Postacute consequences of an infectious disease	Always tired and easily upset; feel pain all over the body and have depression	0.22 (0.15-0.31)	

(O indicates full health; 1 indicates complete loss of health).

\*Reprinted from: Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604-15.

**Household Pulse Survey**- identifies US adults with Long Covid by asking whether they had any of the following symptoms for 3 months or longer that they hadn't had prior to COVID-19: "

Yes" (vs. "No") The HPS identified these symptoms as including the following:

- Tiredness or fatigue,
- difficulty thinking, concentrating, forgetfulness, or memory problems (sometimes referred to as "brain fog"),
- difficulty breathing or shortness of breath,
- joint or muscle pain,
- fast-beating or pounding heart (also known as heart palpitations),
- chest pain,
- dizziness on standing,
- menstrual changes,
- changes to taste/smell, or
- inability to exercise

These symptoms are listed in the US Dept. of Health and Human Services in its Guidance on "Long Covid" as a Disability Under the ADA, Section 504, and Section 1557."

CDC Centers for Disease Control and Prevention

## National Center for Health Statistics

CDC > NCHS > COVID-19 Data from NCHS > Health Care Access, Telemedicine, and Mental Healt

Long COVID

Household Pulse Survey

## Supplement Table 3: YLD and Funding for 70 Conditions

NIH Research, Condition, Disease Categorization (RCDC)	YLD/ 100,000	NIH 2024 \$, millions	NIH Research, Condition, Disease Categorization (RCDC)	YLD/ 100,000	NIH 2024 \$, millions
Alcoholism, Alcohol Use and Health	303.7	639	Infertility	8.4	199
Alzheimer's Disease	279.4	3515	Inflammatory Bowel Disease	43.6	206
Anorexia	23.4	16	Kidney Disease	232.2	708
Anxiety Disorders	675.7	274	Liver Cancer	2.8	978
Arthritis	888.1	324	Long COVID	319.9	80
Asthma	355.7	306	Lung	48.1	2491
Attention Deficit Disorder (ADD)	11.3	87	Lung cancer	25.1	555
Autism	80.9	341	Lymphoma	18.5	347
Brain Cancer	3.7	456	Macular Degeneration	6.6	104
Breast Cancer	77.5	850	Malaria	0.0	225
Cervical Cancer	3.7	171	ME/CFS	598.0	13
Chronic Liver Disease and Cirrhosis	5.6	978	Methamphetamine	18.6	110
Chronic Obstructive Pulmonary Disease	775.3	150	Migraines	739.6	49
Colo-Rectal Cancer	48.7	401	Multiple Sclerosis	40.3	129
Dental/Oral and Craniofacial Disease	467.8	754	Nutrition	38.2	2341
Depression	927.2	702	Otitis Media	11.8	11
Diabetes	1,188.7	1292	Ovarian Cancer	5.5	204
Digestive Diseases	159.3	2708	Pancreatic Cancer	4.6	307
Digestive Diseases - (Gallbladder)	80.2	22	Parkinson's Disease	33.8	277
Digestive Diseases - (Peptic Ulcer)	9.0	9	Perinatal Period, Conditions Originating in	158.0	940
Down Syndrome	2.0	143	Pneumonia	5.6	160
Drug Abuse (NIDA only)	1,140.5	1663	Prescription Drug Abuse	964.5	129
Eating Disorders	85.6	61	Preterm, Low Birth Weight, Newborn Health	123.2	458
Endometriosis	21.1	29	Prostate Cancer	86.9	322
Epilepsy	74.7	244	Psoriasis	127.6	15
Fibroid Tumors (Uterine)	25.4	16	Rheumatoid Arthritis	81.3	95
Headaches	833.3	58	Schizophrenia	397.5	311
Heart Disease - Coronary Heart Disease	120.4	424	Sexually Transmitted Infections	17.3	395
Hepatitis	2.6	378	Sickle Cell Disease	5.5	161
Hepatitis - A	2.1	6	Stroke	433.5	444
Hepatitis - B	0.2	138	Substance Abuse	1,444.2	2597
Hepatitis - C	0.1	113	Suicide	18.4	174
HIV/AIDS	54.2	3294	Tuberculosis	1.5	635
Hodgkin's Disease	2.4	21	Urologic Diseases	49.0	682
Hypertension	47.9	402	Uterine Cancer	16.6	42
			Violence Research	81.1	194